European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Potential 1st Gene Therapy in Europe Directed at Any Type of Hemophilia
Application to be Reviewed Under Accelerated Assessment
SAN RAFAEL, Calif., Dec. 23, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN... Biopharmaceuticals, Regulatory BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: European Medicines Agency (EMA) | Gene Therapy | Genetics | Haemophilia | Hemophilia | Marketing | Pharmaceuticals